We inform you that on this website we use our own and third-party cookies to collect information about its use, improve our services and, where appropriate, display advertising by analyzing your browsing habits. You can expressly accept its use by pressing the "ACCEPT" button or configure and select the cookies you want to accept or reject in the settings. You can also get more information about our cookie policy here.

The global fashion business journal

Apr 26, 202411:28am

Adidas grows 5.4% and rise benefit 24% in H1

The German sportswear group has closed its fist half with a revenue of 11.3 billion euros (12.6 billion dollars).

Aug 8, 2019 — 10:40am
Mds
Save

Adidas grows 4.7% and rise benefit 33% in H1

 

 

Adidas speeds in the first half. The German sportswear giant has closed the second quarter of its fiscal year with a rose of 5.4% in its revenue, up to 11.3 billion euros (12.6 billion dollars).

 

The benefit of the group, on the other hand rose 24% in the period, up to 1.1 billion euros (1.2 billion dollars), while the ebitda arrived at 1.5 billion euros (1.7 billion dollars), 9.7% more.

 

By regions, Asia was the one with the best performance, with a rise of 121%. In Europe, the group stayed the same with a rise of 1.68%, while in North America the rise was 11.7%. In Latin America, on the other hand, the sales of the group rised 3.5%.

 

By brands, Adidas and Reebok had an unequal development during the period. Adidas rised 5.9% its income while Reebok dropped 0.3%.

Advertising
Participation rules

info@themds.com

 

Validation policy for comments: 

 
MDS does not perform prior verification for the publication of comments. However, to prevent anonymous comments from affecting the rights of third parties without the ability to reply, all comments require a valid email address, which won’t be visible or shared.
 
Enter your name and email address to be able to comment on this news: once you click on the link you will find within your verification email, your comment will be published.

0 comments — Be the first to comment
...